UC Berkeley’s Herbert Wertheim School of Optometry and Vision Science integrated the new laser in the beginning of March in its dry eye clinic for treatment of meibomian gland dysfunction.

Michele Andrews, OD, vice president of professional and government affairs for CooperVision, and Terri A. Gossard, OD, MS, member of the AOA board of trustees, sat down with Optometry Times to discuss the goals and tactics of The Myopia Collective.

Community Eye Care Specialists has a total of 6 locations across New York and Pennsylvania providing a variety of medical and surgical services.

The new technology, tailored to creative professionals, reduces the light that passes through the lens without reducing the color of light that is transmitted.

At-home devices challenge commonly held beliefs on IOP measurements, visual field testing, and imaging.

The IOL launch is the company’s second market debut in less than 12 months.

The World Council of Optometry partners with key optometric organizations for 2025 conference and appoints expert leaders in myopia management for education and outreach.

The WVU Health System Board of Directors recently approved $233.5 million to fund the construction of a multi-center outpatient facility with additional exam and testing rooms.

OCU410 utilizes an AAV delivery platform for the retinal delivery of the RORA gene, the company stated in a news release.

What axial length readings and crystalline lens power tell you.

The AI-powered model works to detect early signs of glaucoma and makes iHealthScreen the first company to receive 2 US patents for AMD and glaucoma screening devices.

Evaluating and managing lid margin disease and meibomian gland dysfunction.

Catch up on what happened in optometry during the week of April 15-April 19.

The goal of the grant funding from the Choroideremia Research Foundation is to support validation of functional vision assessments for patients with profound blindness.

The company stated that 46.2% of patients demonstrated a 1- or 2-step improvement in the Diabetic Retinopathy Severity Scale (DRSS) at 40 weeks in the Axpaxli arm, compared to 0% in the control arm.

Analysis showed that patients with dry eye had “worse sleep quality than the healthy population," which could be due to incomplete eyelid closure, eye discomfort, and mental stress.